April 21, 2017 | Richard Pazdur, director of FDA's Oncology Center of Excellence, called for rational approaches to broadening clinical trial eligibility criteria, including enrolling patients aged under 18 in adult trials, to improve cancer studies by capturing the heterogeneity of patient populations that would use therapies after they are approved. BioCentury